Sugary Drinks Linked to Two Liver Cancer Subtypes in Major Pooled Analysis
A pooled study of 1.5M adults finds regular sugary drink consumption raises risk of two liver cancers. Artificial sweeteners showed no link.
Summary
A large pooled analysis of 11 prospective studies covering more than 1.5 million adults found that drinking sugar-sweetened beverages regularly was linked to higher risks of two liver cancer subtypes: hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Each additional sugary drink per day was associated with a 10–15% increased risk of these cancers. Importantly, artificially sweetened beverages showed no significant association with liver cancer. The findings, published in JAMA Network Open and led by researchers at the National Cancer Institute, add to growing evidence that sugary drinks contribute to cancer risk beyond their known effects on obesity and diabetes, suggesting direct metabolic mechanisms may also be involved.
Detailed Summary
Liver cancer is one of the deadlier and harder-to-detect malignancies, making prevention strategies especially important. New research strengthens the case that what you drink daily may meaningfully influence your risk of developing it.
A pooled analysis of 11 prospective cohort studies — encompassing more than 1.5 million adults — found that each additional sugar-sweetened beverage consumed per day was associated with a 10% higher risk of hepatocellular carcinoma (HCC) and a 15% higher risk of intrahepatic cholangiocarcinoma (ICC). These are the two most common primary liver cancer subtypes. Published in JAMA Network Open, the study was led by Dr. Katherine McGlynn of the National Cancer Institute.
A key finding that surprised some researchers: the elevated risk persisted even after adjusting for diabetes and obesity — two well-known consequences of sugary drink consumption and established liver cancer risk factors. This suggests the association is not fully explained by metabolic disease, and that sugar-sweetened beverages may have more direct carcinogenic or pro-inflammatory pathways at play.
Notably, artificially sweetened beverages showed no significant association with liver cancer overall or by subtype. This provides some reassurance for people who use sugar alternatives, though experts caution this should not be interpreted as a full endorsement of artificial sweeteners given other health considerations.
Commentators from Massachusetts General Hospital and Harvard noted these findings solidify an already-growing evidence base linking sugary drinks to cancer outcomes, including prior associations with oral and early-onset colorectal cancer in women.
For health-conscious individuals, the practical message is clear: reducing or eliminating sugar-sweetened beverages is a concrete, low-cost intervention with meaningful cancer-prevention potential. Since these are observational studies, causality cannot be confirmed, but the consistency across multiple large cohorts makes the association compelling and actionable.
Key Findings
- Each daily sugary drink was linked to 10% higher hepatocellular carcinoma risk and 15% higher cholangiocarcinoma risk.
- Risk associations persisted after adjusting for obesity and diabetes, suggesting mechanisms beyond metabolic disease.
- Artificially sweetened beverages showed no significant association with liver cancer in this analysis.
- Findings come from a pooled analysis of 11 studies covering over 1.5 million adults, strengthening evidence quality.
- Reducing sugar-sweetened beverage intake is recommended based on this and prior cancer-association research.
Methodology
This is a news report summarizing a peer-reviewed pooled analysis of 11 prospective cohort studies published in JAMA Network Open. The evidence basis is strong given the large sample size exceeding 1.5 million adults and multi-cohort design. Source credibility is high — MedPage Today is a reputable medical news outlet and the primary study originates from the National Cancer Institute.
Study Limitations
Observational cohort studies cannot establish causality, only association. The article does not provide full details on confounding variables or population diversity across the 11 cohorts. Readers should consult the primary JAMA Network Open publication for full methodology and subgroup analyses.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.